June 2, 2020 / 12:52 PM / a month ago

BRIEF-Mirum’S Maralixibat Shows Transplant-Free Survival For Pediatric Patients With Progressive Familial Intrahepatic Cholestasis

June 2 (Reuters) - Mirum Pharmaceuticals Inc:

* MIRUM’S MARALIXIBAT DEMONSTRATES TRANSPLANT-FREE SURVIVAL FOR PEDIATRIC PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS

* MIRUM PHARMACEUTICALS INC - MARALIXIBAT-TREATED PATIENTS ACHIEVING SERUM BILE ACID CONTROL HAVE FIVE-YEAR NATIVE LIVER SURVIVAL AFTER TREATMENT

* MIRUM PHARMACEUTICALS- DATA DEMONSTRATE MARALIXIBAT LEADS TO NORMALIZATION, REDUCTIONS OF LIVER ENZYMES, REDUCED PRURITUS, AND IMPROVED GROWTH Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below